Skip to content
Sharism- Lifestyle
Author:
Avalyn Pharma Inc.
Avalyn Announces First Patient Dosed in AURA Phase 2 Clinical Trial Evaluating AP02, Inhaled Nintedanib, for the Treatment of Idiopathic Pulmonary Fibrosis
March 23, 2026
←
Previous Page
1
2